Stockholm-based QuTEM has reached a critical milestone in its mission to improve the quality and safety of next-generation medicines. A new peer-reviewed study, published in Molecular Therapy: Methods & Clinical Development, highlights QuTEM’s innovative electron microscopy technology and image analysis as a reliable and precise standard for analyzing the building blocks of gene therapy.

This breakthrough originates from QuTEM’s proprietary technology. In collaboration with Viralgen SL, a leader in the manufacturing of gene therapy vectors, Viralgen applied complementary analytical methods that further confirmed QuTEM’s breakthrough. The study demonstrated that QuTEM’s method is more reliable than several established techniques, underscoring its potential as a new benchmark for quality control in gene therapy.

Peter Almberg, Chairman of Katalysen Ventures, expressed his enthusiasm: 'QuTEM is a real success story in our portfolio. We have observed how QuTEM has evolved from an imaging company to, today, being an analytics company with its own proprietary software developed in-house, Gridsee, and immense amounts of unique data collected over 15+ years. As investors, we see that from such a position QuTEM is uniquely placed to extract increasing value from its analytical capabilities and insights. An undeniable prerequisite is first to achieve gold-standard status in the industry.'

Josefina Nilsson, CEO of QuTEM, added, 'This recognition confirms QuTEM’s role as a potential golden standard for quality control in gene therapy. The fact that Viralgen, a leader in AAV manufacturing, together with other major pharmaceutical companies, have decided to outsource an essential part of their quality control to us demonstrates that QuTEM’s innovative approach is already embraced by the industry’s most respected players.'

For investors, this milestone highlights QuTEM’s growing relevance in a rapidly expanding global market. The gene therapy sector is forecast to see strong growth in the coming decade, and demand for reliable quality control tools is set to rise sharply. With confirmation from both the scientific community and leading players in gene therapy manufacturing, QuTEM is well positioned to play a central role in ensuring the safety, consistency, and success of future therapies.

Peter Almberg concludes, 'QuTEM's long-term trajectory is extremely exciting for investors. It is one of our core investments, and our holding is approximately 15% of the company. The fact that the company is now profitable, while at the same time adding a new sales model that significantly increases global scalability, makes QuTEM’s outlook all the more compelling.'

Given QuTEM's advancements and strategic positioning, investors should consider holding their current investments as the company continues to establish itself as a leader in gene therapy quality control.